|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Gourin CG and Podolsky RH: Racial
disparities in patients with head and neck squamous cell carcinoma.
Laryngoscope. 116:1093–1106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
4
|
Adjuvant chemotherapy for advanced head
and neck squamous carcinoma. Final report of the Head and Neck
Contracts Program. Cancer. 60:301–311. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah JP and Lydiatt W: Treatment of cancer
of the head and neck. CA Cancer J Clin. 45:352–368. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lavertu P, Adelstein DJ, Saxton JP, Secic
M, Eliachar I, Strome M, Larto MA and Wood BG: Aggressive
concurrent chemoradiotherapy for squamous cell head and neck
cancer: an 8-year single-institution experience. Arch Otolaryngol
Head Neck Surg. 125:142–148. 1999.PubMed/NCBI
|
|
7
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin JH, Deng H, Huang Q and Morser J:
KIAP, a novel member of the inhibitor of apoptosis protein family.
Biochem Biophys Res Commun. 279:820–831. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Badran A, Yoshida A, Ishikawa K, Goi T,
Yamaguchi A, Ueda T and Inuzuka M: Identification of a novel splice
variant of the human anti-apoptosis gene survivin. Biochem Biophys
Res Commun. 314:902–907. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eckelman BP, Salvesen GS and Scott FL:
Human inhibitor of apoptosis proteins: why XIAP is the black sheep
of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roy N, Deveraux QL, Takaahashi R, Salvesen
GS and Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct
inhibitors of specific caspases. EMBO J. 16:6914–6925. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vaux DL and Silke J: Mammalian
mitochondrial IAP binding proteins. Biochem Bioph Res Commun.
304:499–504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta
A, Wierzbowska A and Robak T: The inhibitor of apoptosis protein
family and its antagonists in acute leukemias. Apoptosis.
9:705–715. 2004.PubMed/NCBI
|
|
14
|
Yan B: Research progress on Livin protein:
an inhibitor of apoptosis. Mol Cell Biochem. 357:39–45. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv J and Chen ZC: Resent research about
Livin in cancer. Chin J Cancer Prev Treat. 13:1347–1350. 2006.
|
|
16
|
Ashhab Y, Alian A, Polliack A, Panet A and
Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis
gene with different biological properties and tissue distribution
pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yagihashi A, Ohmura T, Asanuma K,
Kobayashi D, Tsuji N, Torigoe T, Sato N, Hirata K and Watanabe N:
Detection of auto-antibodies to survivin and livin in sera from
patients with breast cancer. Clin Chim Acta. 362:125–130. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hariu H, Hirohashi Y, Toriegoe T, Asanuma
H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K,
Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N and Sato
Nl: Aberrant expression and potency as a cancer immunotherapy
target of inhibitor of apoptosis protein family, Livin/ML-IAP in
lung cancer. Clin Cancer Res. 11:1000–1009. 2005.PubMed/NCBI
|
|
19
|
Chung CY, Park YL, Kim N, Park HC, Park
HB, Myung DS, Kim JS, Cho SB, Lee WS and Joo YE: Expression and
prognostic significance of Livin in gastric cancer. Oncol Rep.
30:2520–2528. 2013.PubMed/NCBI
|
|
20
|
Qiuping Z, Jei X, Youxin J, Wei J, Chun L,
Jin W, Qun W, Yan L, Chungsong H, Mingzhen Y, Qingping G, Kejian Z,
Qun L, Junyan L and Jinguan T: CC chemokine ligand 25 enhances
resistance to apoptosis in CD4+ T cells from patients
with T-cell lineage acute and chronic lymphocytic leukemia by means
of livin activation. Cancer Res. 64:7579–7587. 2004.PubMed/NCBI
|
|
21
|
Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH,
Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY and Ahn HS: Expression of
Livin, an antiapoptotic protein, is an independent favorable
prognostic factor in childhood acute lymphoblastic leukemia. Blood.
109:471–477. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gazzaniga P, Gradilone A, Giuliani L,
Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò
AM: Expression and prognostic significance of LIVIN, SURVIVIN and
other apoptosis-related genes in the progression of superficial
bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim DK, Alvarado CS, Abramowsky CR, Gu L,
Zhou M, Soe MM, Sullivan K, George B, Schemankewitz E and Findly
HW: Expression of inhibitor-of-apoptosis protein (IAP) livin by
neuroblastoma cells: correlation with prognostic factors and
outcome. Pediatr Dev Pathol. 8:621–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gordon GJ, Mani M, Mukhopadhyay L, Dong L,
Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ and Bueno R:
Expression patterns of inhibitor of apoptosis proteins in malignant
pleural mesothelioma. J Pathol. 211:447–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lopes RB, Gangeswaran R, McNeish IA, Wang
Y and Lemoine NR: Expression of the IAP protein family is
dysregulated in pancreatic cancer cells and is important for
resistance to chemotherapy. Int J Cancer. 120:2344–2352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nedelcu T, Kubista B, Koller A, sutzbacher
I, Mosberger I, Arrich F, Trieb K, Kotz R and Toma CD: Livin and
Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin
Oncol. 2:237–244. 2008.PubMed/NCBI
|
|
27
|
Crnković-Mertens I, Wagener N, Semzow J,
Grőne EF, Haferkamp A, Hohenfellner M, Butz K and Hoppe-Seyler F:
Targeted inhibition of Livin resensitizes renal cancer cells
towards apoptosis. Cell Mol Life Sci. 64:1137–1144. 2007.PubMed/NCBI
|
|
28
|
Kempkensteffen C, Hinz S, Christoph F,
Krause H, Koellemann J, Magheli A, Schrader M, Schostak M, Miller K
and Weikert S: Expression of the apoptosis inhibitor livin in renal
cell carcinomas: correlations with pathology and outcome. Tumor
Biol. 28:132–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Myung DS, Park YL, Chung CY, Park HC, Kim
JS, Cho SB, Lee WS, Lee KH, Lee JH and Joo YE: Expression of Livin
in colorectal cancer and its relationship to tumor cell behavior
and prognosis. PLoS One. 8:e732622013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Chen N, Wang X, He Y, Chen X, Huang
Y, Yin W and Zhou Q: Apoptosis and proliferation markers in
diffusely infiltrating astrocytomas: profiling of 17 molecules. J
Neuropathol Exp Neurol. 65:905–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang R, Lin F, Wang X, Gao P, Dong K, Zou
AM, Cheng SY, Wei SH and Zhang HZ: Silencing Livin gene expression
to inhibit proliferation and enhance chemosensitivity in tumor
cells. Cancer Gene Ther. 15:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiang Y, Yao H, Wang S, Hong M, He J, Cao
S, Min H, Song E and Guo X: Prognostic value of Survivin and Livin
in nasopharyngeal carcinoma. Laryngoscope. 116:126–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer - Cancer
Staging Manual. 7th edition. Springer; New York: pp. 6492010
|
|
34
|
Kenneth NS and Duckett CS: IAP proteins;
regulators of cell migration and development. Curr Opin Cell Biol.
24:871–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Green D and Kroemer G: The central
executioners of apoptosis: caspases or mitochondrial. Trends Cell
Bio. 8:267–271. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xi RC, Biao WS and Gang ZZ: Significant
elevation of survivin and livin expression in human colorectal
cancer: inverse correlation between expression and overall
survival. Onkologie. 34:428–432. 2011. View Article : Google Scholar
|
|
37
|
Kasof GM and Gomes BC: Livin, a novel
inhibitor of apoptosis protein family member. J Biol Chem.
276:3238–46. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun JG, Liao RX, Zhang SX, Duan YZ, Zhuo
WL, Wang XX, Wang ZX, Li DZ and Chen ZT: Role of inhibitor of
apoptosis protein Livin in radiation response in nonsmall cell lung
cancer. Cancer Biother Radiopharm. 26:585–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Zhang Q, Liu B, Han M and Shan B:
Challenge and promise: roles for Livin in progression and therapy
of cancer. Mol Cancer Ther. 7:3661–3669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang H and Schimmer AD: Livin/melanoma
inhibitor of apoptosis protein as a potential therapeutic target
for the treatment of malignancy. Mol Cancer Ther. 6:24–30. 2007.
View Article : Google Scholar
|
|
41
|
Liu B, Han M, Wen JK and Wang L:
Livin/ML-IAP as a new target for cancer treatment. Cancer Lett.
250:168–176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wagener N, Crnković-Mertens I, Vetter C,
Macher-Gőppinger S, Bedke J, Grőne EF, Zentgraf H, Pritsch M,
Hoppe-Seyler K, Buse S, Haferkamp A, Autschbach F, Hohenfellner M
and Hoppe-Seyler F: Expression of inhibitor of apoptosis protein
Livin in renal cell carcinoma and non-tumorous adult kidney. Br J
Cancer. 97:1271–1276. 2007. View Article : Google Scholar : PubMed/NCBI
|
